Vancouver, BC (August 31, 2022) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that a poster presentation on the Company’s lead drug candidate Halneuron was accepted for presentation at the International Association for the Study of Pain (IASP)